Indoco RemediesNSE:INDOCO -0.01%71 Gross Margin % is 69.07% as of Mar. 2026, which is 2% above its 10-year median of 67.74. GuruFocus rates NSE:INDOCO with a GF Score™ of 71/100 and a GF Value™ of ₹358.45 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 938 Drug Manufacturers companies, Indoco Remedies ranks better than 81.45% on this metric.
The historical rank and industry rank for Indoco Remedies's Gross Margin % or its related term are showing as below:
NSE:INDOCO'
s Gross Margin % Range Over the Past 10 Years
Min: 64.45 Med: 67.74 Max: 69.78
Current: 69.76
During the past 13 years, the highestGross Margin % of Indoco Remedies was 69.78%. The lowest was 64.45%. And the median was 67.74%.
NSE:INDOCO's Gross Margin % is ranked better than 81.45% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:INDOCO: 69.76
Indoco Remedies had a gross margin of 69.07% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Indoco Remedies was 0.20% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Indoco Remedies had a gross margin of 69.07% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Indoco Remedies Gross Margin % Related Terms
Indoco Remedies Gross Margin % Historical Data
* Premium members only.
The historical data trend for Indoco Remedies's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDOCO vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Indoco Remedies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indoco Remedies Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indoco Remedies's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Indoco Remedies's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Indoco Remedies (NSE:INDOCO) has a Gross Margin % of 69.07% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Indoco Remedies and its competitors. This is near median its historical median of 67.74. Over the past decade, Indoco Remedies' Gross Margin % has ranged from 64.45 to 69.78. According to the industry distribution chart, Indoco Remedies ranks #174 out of 938 companies in the Drug Manufacturers industry, placing it in the top 18.6%.
Is Indoco Remedies' Gross Margin % too high?
Indoco Remedies' current Gross Margin % of 69.07% is near median its 10-year median of 67.74. Over the past 10 years, this metric has ranged from a low of 64.45 to a high of 69.78. The Drug Manufacturers industry median Gross Margin % is 48.54. Indoco Remedies' value of 69.07% is 42.3% above this industry median. Based on the distribution chart, Indoco Remedies ranks #174 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Indoco Remedies has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indoco Remedies' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Indoco Remedies ranks #174 out of 938 companies for Gross Margin %. This places Indoco Remedies in the top 19% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Indoco Remedies' value of 69.07% is 42.3% above this benchmark. Historically, Indoco Remedies' own Gross Margin % has ranged from 64.45 to 69.78 over the past decade. While the company's 10-year median is 67.74 vs. the industry median of 48.54, Indoco Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indoco Remedies's current Gross Margin % of 69.07% is 42.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Indoco Remedies and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indoco Remedies's current Gross Margin % is 69.07%, which is near median its own 10-year median of 67.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indoco Remedies stock overvalued right now?
Based on GuruFocus' analysis, Indoco Remedies (NSE:INDOCO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹358.45, compared to a current price of ₹244.00 — trading 31.9% below its estimated fair value. The current Gross Margin % is 69.07%, which is near median its 10-year median of 67.74 and 42.3% above the Drug Manufacturers industry median of 48.54. Indoco Remedies' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Indoco Remedies (NSE:INDOCO), the current Gross Margin % is 69.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indoco Remedies (NSE:INDOCO) Overvalued in 2026?
Based on GuruFocus' analysis, Indoco Remedies stock appears to be undervalued.
The current stock price of ₹244.00 is trading 31.9% below its estimated GF Value™ of ₹358.45.
GuruFocus considers Indoco Remedies to be Possible Value Trap.
Key valuation signals for NSE:INDOCO:
Gross Margin %: 69.07% (near median its 10-year median of 67.74)
GF Value™: ₹358.45 vs. price of ₹244.00 (31.9% below fair value)
Industry Position: 42.3% above the Drug Manufacturers median (#174 of 938)
No single metric tells the full story. See the NSE:INDOCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indoco Remedies Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company manufactures products for different therapeutic sectors including Gastroenterology, Dentistry & Stomatology, Respiratory, Diabetology, Women's Health, Nutritional products, Cardiology, Metabolic Disorders, and Primary Care medicines. The only operating segment of the company is Pharmaceutical Products. Geographically, it generates the majority of the revenue from India.
71GF Score
Get the complete analysis for NSE:INDOCO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDOCO has been successfully added to your 
